Arrayed CRISPR Screening for Revolutionizing Target Discovery

In this interview conducted at SLAS EU 2023 in Brussels, Belgium, we spoke to Ulrike Kuenzel, Associate Director in the Functional Genomics department at AstraZeneca about the application of arrayed CRISPR screening for target identification and more.

Targeting the “don’t eat me” signal may improve immunotherapy for glioblastoma

“Don’t eat me!” That’s how one might translate the signal that the cancer cells in a glioblastoma send to the macrophages (white blood cells specialized

July 19, 2023

Gerresheimer remains on track in 1st half year 2024 – Biotech Investments

EQS-News: Gerresheimer AG / Key word(s): Half Year Results Gerresheimer remains on track in 1st half year 2024 11.07.2024 / 07:00 CET/CEST The issuer is

July 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Arrayed CRISPR Screening for Revolutionizing Target Discovery

Targeting the “don’t eat me” signal may improve immunotherapy for glioblastoma

Popular diabetes drugs not linked to thyroid cancer risk, study finds

Gerresheimer remains on track in 1st half year 2024 – Biotech Investments

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe